Autoantibodies directed against CD43 molecules with an altered glycosylation status on human immunodeficiency virus type 1 (HIV-1)-infected CEM cells are found in all HIV-1+ individuals. 1995

V Giordanengo, and M Limouse, and L Desroys du Roure, and J Cottalorda, and A Doglio, and A Passeron, and J G Fuzibet, and J C Lefebvre
Laboratoire de Virologie, Faculté de Médecine, Centre de Dépistage Anonyme et Gratuit, Hôpital St Roch, Nice, France.

Autoantibodies to lymphocytes have been detected in sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals, and several autoantigens have been described. Among them, hyposialylated CD43 has been shown to be a target for autoantibodies in up to 47% of HIV+ individuals. However, the corresponding autoantigen (ie, the incompletely sialylated CD43) has not been isolated from blood cells of HIV-1-infected individuals. Recently, we have observed in vitro that HIV-1 productively or latently infected CEM cells (CEMLAI/NP) express CD43 molecules with modified glycosylation (mogly CD43). Using CEMLAI/NP cells, which do not express any structural viral antigen, we show now that all of the tested HIV+ sera from asymptomatic individuals, and up to 86% of those from subjects at the acquired immunodeficiency syndrome stage contain antibodies (mainly IgM and, to a lesser degree, IgG) that recognize the surface of CEMLAI/NP cells, and precipitate mogly CD43 molecules from the cells lysates. Taken together with our previous demonstration of altered glycosylation of CD43 from HIV-1-infected CEM cells in vitro, the constant antimogly CD43 autoimmune response observed from asymptomatic HIV-1+ subjects is likely to illustrate the occurrence of an altered glycosylation in vivo of the major lymphocyte surface CD43 glycoprotein, associated with HIV-1 infection.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D006031 Glycosylation The synthetic chemistry reaction or enzymatic reaction of adding carbohydrate or glycosyl groups. GLYCOSYLTRANSFERASES carry out the enzymatic glycosylation reactions. The spontaneous, non-enzymatic attachment of reducing sugars to free amino groups in proteins, lipids, or nucleic acids is called GLYCATION (see MAILLARD REACTION). Protein Glycosylation,Glycosylation, Protein
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency

Related Publications

V Giordanengo, and M Limouse, and L Desroys du Roure, and J Cottalorda, and A Doglio, and A Passeron, and J G Fuzibet, and J C Lefebvre
October 1990, The Journal of experimental medicine,
V Giordanengo, and M Limouse, and L Desroys du Roure, and J Cottalorda, and A Doglio, and A Passeron, and J G Fuzibet, and J C Lefebvre
June 1991, Clinical immunology and immunopathology,
V Giordanengo, and M Limouse, and L Desroys du Roure, and J Cottalorda, and A Doglio, and A Passeron, and J G Fuzibet, and J C Lefebvre
June 2019, Pharmaceutics,
V Giordanengo, and M Limouse, and L Desroys du Roure, and J Cottalorda, and A Doglio, and A Passeron, and J G Fuzibet, and J C Lefebvre
October 2001, The Journal of general virology,
V Giordanengo, and M Limouse, and L Desroys du Roure, and J Cottalorda, and A Doglio, and A Passeron, and J G Fuzibet, and J C Lefebvre
November 2002, Endocrine,
V Giordanengo, and M Limouse, and L Desroys du Roure, and J Cottalorda, and A Doglio, and A Passeron, and J G Fuzibet, and J C Lefebvre
January 1991, Blood,
V Giordanengo, and M Limouse, and L Desroys du Roure, and J Cottalorda, and A Doglio, and A Passeron, and J G Fuzibet, and J C Lefebvre
October 1990, The Journal of general virology,
V Giordanengo, and M Limouse, and L Desroys du Roure, and J Cottalorda, and A Doglio, and A Passeron, and J G Fuzibet, and J C Lefebvre
July 1988, Aviation, space, and environmental medicine,
V Giordanengo, and M Limouse, and L Desroys du Roure, and J Cottalorda, and A Doglio, and A Passeron, and J G Fuzibet, and J C Lefebvre
August 1995, The Journal of clinical investigation,
V Giordanengo, and M Limouse, and L Desroys du Roure, and J Cottalorda, and A Doglio, and A Passeron, and J G Fuzibet, and J C Lefebvre
August 1999, Journal of virology,
Copied contents to your clipboard!